NO20012567L - Azepinoindolderivater, fremstilling og anvendelse derav - Google Patents

Azepinoindolderivater, fremstilling og anvendelse derav

Info

Publication number
NO20012567L
NO20012567L NO20012567A NO20012567A NO20012567L NO 20012567 L NO20012567 L NO 20012567L NO 20012567 A NO20012567 A NO 20012567A NO 20012567 A NO20012567 A NO 20012567A NO 20012567 L NO20012567 L NO 20012567L
Authority
NO
Norway
Prior art keywords
preparation
azepinoindole derivatives
azepinoindole
derivatives
forms
Prior art date
Application number
NO20012567A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012567D0 (no
Inventor
Wilfred Lubisch
Michael Kock
Thomas Hoeger
Sabine Schult
Roland Grandel
Reinhold Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20012567D0 publication Critical patent/NO20012567D0/no
Publication of NO20012567L publication Critical patent/NO20012567L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20012567A 1999-09-28 2001-05-25 Azepinoindolderivater, fremstilling og anvendelse derav NO20012567L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
PCT/EP2000/009024 WO2001023390A2 (de) 1999-09-28 2000-09-15 Azepinoindol-derivate, deren herstellung und anwendung

Publications (2)

Publication Number Publication Date
NO20012567D0 NO20012567D0 (no) 2001-05-25
NO20012567L true NO20012567L (no) 2001-06-25

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012567A NO20012567L (no) 1999-09-28 2001-05-25 Azepinoindolderivater, fremstilling og anvendelse derav

Country Status (17)

Country Link
EP (1) EP1183259A2 (hu)
JP (1) JP2003510328A (hu)
KR (1) KR20010087401A (hu)
CN (1) CN1374961A (hu)
AU (1) AU1271201A (hu)
BG (1) BG105650A (hu)
BR (1) BR0007174A (hu)
CA (1) CA2352194A1 (hu)
CZ (1) CZ20012373A3 (hu)
HK (1) HK1048999A1 (hu)
HU (1) HUP0104917A3 (hu)
IL (1) IL143349A0 (hu)
NO (1) NO20012567L (hu)
PL (1) PL347885A1 (hu)
SK (1) SK8842001A3 (hu)
TR (1) TR200101499T1 (hu)
WO (1) WO2001023390A2 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE50310378D1 (de) 2002-07-26 2008-10-02 Basf Plant Science Gmbh Neue selektionsverfahren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
CN102107008B (zh) 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
EP2166100B1 (en) 2005-03-08 2012-07-18 BASF Plant Science GmbH Expression enhancing intron sequences
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
HUE030800T2 (hu) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd 514 számú gyógyszerkészítmény
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN102686726B (zh) 2009-11-27 2015-12-16 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
BR112012012444A2 (pt) 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor, organismo não humano, método para fornecer uma endonuclease quimérica, método para recombinação homóloga de polinucleotídeos, método para mutação alvejada de polinucleotídeosa e método para recombinação homóloga ou mutação alvejada"
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021015149A2 (pt) * 2019-02-02 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Análogo de indolo heptamil oxima como inibidor de parp
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
SI20691B (sl) * 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
BG105650A (en) 2002-02-28
CN1374961A (zh) 2002-10-16
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
TR200101499T1 (tr) 2002-09-23
WO2001023390A2 (de) 2001-04-05
AU1271201A (en) 2001-04-30
IL143349A0 (en) 2002-04-21
NO20012567D0 (no) 2001-05-25
JP2003510328A (ja) 2003-03-18
CZ20012373A3 (cs) 2002-05-15
HUP0104917A2 (hu) 2002-04-29
SK8842001A3 (en) 2002-01-07
PL347885A1 (en) 2002-04-22
HK1048999A1 (zh) 2003-04-25
EP1183259A2 (de) 2002-03-06
WO2001023390A3 (de) 2001-12-27
KR20010087401A (ko) 2001-09-15
HUP0104917A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
NO20012567L (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EE200200710A (et) Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20073465L (no) Benzotiazol-derivater
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
DE60005054D1 (de) Chinuclidin-acrylamide
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
NO990662L (no) Trombin-inhibitorer
NO20005264D0 (no) Heterocyklisk substituerte amider, deres fremstilling og anvendelse
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BR9813719A (pt) Agentes terapêuticos
HUP0203855A3 (en) Substituted piperazine derivatives as mtp inhibitors
DK1463731T3 (da) Dibenzodiazepinderivater, deres fremstilling og anvendelse
NO20003960D0 (no) Salter av paroksetin
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application